Your browser doesn't support javascript.
loading
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022.
Huiberts, Anne J; de Gier, Brechje; Hoeve, Christina E; de Melker, Hester E; Hahné, Susan Jm; den Hartog, Gerco; van de Wijgert, Janneke Hhm; van den Hof, Susan; Knol, Mirjam J.
Affiliation
  • Huiberts AJ; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • de Gier B; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Hoeve CE; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • de Melker HE; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • Hahné SJ; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • den Hartog G; Radboud Centre for Infectious Diseases, Radboudumc, Nijmegen, the Netherlands.
  • van de Wijgert JH; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
  • van den Hof S; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht (UMCU), Utrecht, the Netherlands.
  • Knol MJ; Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.
Euro Surveill ; 28(7)2023 02.
Article in En | MEDLINE | ID: mdl-36795500
ABSTRACT
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 Type of study: Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 Type of study: Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Year: 2023 Type: Article